EMJ Oncology 9 [Supplement 2] . 2021

In this issue

ONCOGENESIS in cholangiocarcinoma, a rare cancer, can be driven by the oncometabolite D-2-hydroxyglutarate, produced as a result of mutations in the isocitrate dehydrogenase 1 gene (IDH1). Dr Andrew X. Zhu delivered an oral presentation at the 2021 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI 2021) entitled ‘Final Results from ClarIDHy, a Global, Phase III, Randomised, Double-Blind Study of Ivosidenib vs Placebo in Patients with Previously Treated Cholangiocarcinoma and an Isocitrate Dehydrogenase 1 (IDH1) Mutation’.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given